tbuckley/cabot-search huggingface dataset:
222P The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Authors: N. Hayakawa, G. Kaneko, R. Yamashita, D. Ikarashi, Y. Endo, W. Obara, M. Oyama, Y. Kondo, E. Kikuchi
Journal: Annals of Oncology (2023)
202P Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Authors: R. Li, W. Li, G. Yuan, Q. Li, X. Hu, P. Zhu, Y. Chen, K. Su, Y. Guo, M. Zang, J. Chen
Journal: Annals of Oncology (2023)
The efficacy of mindfulness apps on symptoms of depression and anxiety: An updated meta-analysis of randomized controlled trials
Authors: Jake Linardon, Mariel Messer, Simon B. Goldberg, Matthew Fuller-Tyszkiewicz
Journal: Clinical Psychology Review (2023)

Mindfulness apps have become popular tools for addressing symptoms of depression and anxiety. Since the publication of earlier meta-analyses evaluating the efficacy of mindfulness apps for depression and anxiety symptoms, over 20 randomized controlled trials (RCTs) have been conducted. There is a need for an updated meta-analysis that quantifies the effects of mindfulness apps on these symptoms and tests for potential moderators.. Random effects meta-analyses were conducted on 45 RCTs. Small, significant effect sizes were found for symptoms of depression (N
ASCEND-Eye
Authors: Emily L. Sammons, Georgina Buck, Louise J. Bowman, William M. Stevens, Imen Hammami, Sarah Parish, Jane Armitage, Emily Sammons, Louise Bowman, William Stevens, Georgina Buck, Imen Hammami, Sarah Parish, Jane Armitage, R. Collins, J. Armitage, J. Barton, D. Simpson, A. Adler, T. Aung, C. Baigent, H.J. Bodansky, A. Farmer, R. Haynes, R. McPherson, M. Mafham, H.A.W. Neil, N. Samani, P. Sleight, P. Weissberg, P. Sandercock, H. Gerstein, R. Gray, C. Hennekens, L. Fletcher, K. Murphy, S. Hurley, R. Lee, S. Pickworth, M. Willett, M. Wincott, M. Lay, G. Buck, A. Murawska, W. Stevens, K. Wallendszus, A. Young, I. Hammami, G. Brown, J. Latham-Mollart, A. Brewer, P. Scanlon, P. Patel, M. Olson, J. Kay, S. Banerjee, L. Evans, A. Davies, M. Griffiths, H. Clayton, P. Kirby, M. Pennington, D. Clarke, J. Anslow, A. Hallam, J. Witts, S. Egan, A. Wharton, A. Sachdev, A. Derbyshire, E. Williamson, K. Hepplestone, S. Mithra, S. Oliver, P. Wiatrak-Olszewska, T. Gazis, K. Alvey, E. Wu, H. Cook, N. Gregory, P. Parkinson, J. Anderson, L. Bolter, P. Maharajan, R. McFee, L. Allsop, D. Sowter, D. Hodgson, J. Thow, J. Featonby, R. Furnival, H. Lipinski, H. Benjamin, T. McAfee, E. Payne, L. Still
Journal: Ophthalmology (2023)
211MO EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
Authors: T.B. Powles, B. Perez Valderrama, S. Gupta, J. Bedke, E. Kikuchi, J. Hoffman-Censits, G. Iyer, C. Vulsteke, S.H. Park, S.J. Shin, D.E. Castellano Gauna, G. Fornarini, J-R. Li, M. Gumus, N. Mar, S. Narayanan, X. Yu, S. Gorla, B. Homet Moreno, M.S. van der Heijden
Journal: Annals of Oncology (2023)
257O Association of enzalutamide (ENZA) duration of treatment (DOT) and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis from PREVAIL
Authors: E. Chiong, C.S. Kim, Y.D. Choi, B. Tombal, M. Lian, G. Gourgioti, A. Dhar, Z. Xiao, F. Zohren, T. Beer
Journal: Annals of Oncology (2023)
219P Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Authors: P. Dong, T. Huang, L. Jiang, W. Wei, X. Zheng, Z. Zhang, S. Guo, H. Han, F. Zhou
Journal: Annals of Oncology (2023)
233P The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Authors: A.H. Al Sharie, L. Lataifeh, S. Alzghoul, E. Al Masoud, S. Bashammakh, B. Abu Mousa
Journal: Annals of Oncology (2023)
210MO Low dose nivolumab with TKI in mRCC: Dosing strategies, de-escalation and survival among self-paying patients in India
Authors: A.O. John, J.T. Georgy, A. Joel, D.B. Thumaty, J.P. Wisely, N. Tj, S. Kumar, R.T. Chacko, R.S. Ninan, A. Chandramohan, B. Yadav, A. Singh
Journal: Annals of Oncology (2023)
261MO Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume, metastatic hormone-sensitive prostate cancer receiving rezvilutamide in the CHART trial
Authors: D. Ye, S. Jiang, H. Luo, P. Dong, Z. Wang, N-Z. Xing, T. Ma, Z. Wang, X. Gu, G. Zhou, X. Xue, Z. Sun, J. Guo, Y. Yang, C. Wang, G. Shan, A. Zhang, D. Ding, J. Lian, W. Wang
Journal: Annals of Oncology (2023)
239P Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Authors: R. Mizuno, Y. Yasumizu, N. Tanaka, S. Morita, T. Takeda, K. Matsumoto, T. Kosaka, H. Asanuma, M. Oya
Journal: Annals of Oncology (2023)
213P Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Authors: K. Takemura, T. Yuasa, A. Lemelin, E. Ferrier, J.C. Wells, E. Saad, R.M. Saliby, N.S. Basappa, L.A. Wood, E. Jude, S.K. Pal, F. Donskov, B. Beuselinck, B.E. Szabados, T.B. Powles, R.R. McKay, G. Gebrael, N. Agarwal, T.K. Choueiri, D.Y.C. Heng
Journal: Annals of Oncology (2023)
314P Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Authors: U. Palo, D. Mondal, A. Ghosh, B. Chakraborti, J. Mishra, J. Ghosh, S. Roy, J. Bhaumik
Journal: Annals of Oncology (2023)
266P Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Authors: W.K.P. Kwong, D.M.C. Poon, T. Chan, F.Y. Cheung, H.S. Chung, C.S. Ho, H.C.M. Lam, K. Law, A. Leung, L.H. Tse, T. Yuen
Journal: Annals of Oncology (2023)
288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Authors: K. Fujiwara, B.M. Slomovitz, A. Gonzalez Martin, E. Kalbacher, A. Bagameri, S. Ghamande, J-Y. Lee, S. Banerjee, F.C. Maluf, D. Lorusso, K. Yonemori, E. van Nieuwenhuysen, L.M. Manso Sanchez, L. Woelber, A.M. Westermann, A. Covens, E. Whalley, M.S.L. Teng, I. Soumaoro, I.B. Vergote
Journal: Annals of Oncology (2023)
309P Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Authors: H. Fujii, T. Nishikawa, H. Yoshida, R. Ozawa, M. Hoshino, A. Saito, M. Ito, S. Kita, A. Maejima, Y. Kojima, K. Sudo, T. Shimoi, K. Yonemori
Journal: Annals of Oncology (2023)
274P Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Authors: J. Akatsuka, Y. Ogata, Y. Endo, T. Tsuchiya, M. Taniuchi, S. Ikuma, M. Shibasaki, H. Hasegawa, H. Mikami, M. Yanagi, H. Takeda, Y. Toyama, G. Kimura, Y. Kondo
Journal: Annals of Oncology (2023)
268P Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Authors: H.I. Chou, L. Lu, C.T. Chung, J.S.K. Chan, R.N.C. Chan, Y.H.A. Lee, E.C. Dee, K. Ng, H.H.H. Pui, S. Lee, B. Cheung, G. Tse, J. Zhou
Journal: Annals of Oncology (2023)
305P A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Authors: Y. Nagase, S. Nakagawa, Y. Ueda, H. Ogimoto, M. Kobayashi, M. Shiomi, R. Kakubari, A. Otake, E. Yoshioka, M. Watanabe, T. Egawa-Takata, S. Matsuzaki, S. Koyama, T. Yokoi, K. Amemiya, K. Ito, S. Kamiura, T. Kimura
Journal: Annals of Oncology (2023)
519P Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Authors: Y. Cheng, J. Wang, W. Yao, Y. Yu, A. Zang, L. Cao, D. Lv, S. Li, Z. Meng, J. Zhang, Q. Guo, D. Huang, A. Liu, J. Liu, W. Mao, K. Tang, Y. Zhang, E. Chen, Z. Wang, J. Zheng
Journal: Annals of Oncology (2023)
552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Authors: M-J. Ahn, B.C. Cho, Y. Goto, K. Yoh, W-C. Su, J. Shimizu, J-S. Lee, S. Oizumi, J.C-H. Yang, H. Hayashi, H. Zebger-Gong, K. Sugiura, L. Lan, C. Liu, S. Kitazono
Journal: Annals of Oncology (2023)
LBA1 Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK+ non-small cell lung cancer (NSCLC): A sub analysis of ALINA
Authors: J.S. Ahn, Y-L. Wu, R. Dziadziuszko, F. Barlesi, M. Nishio, D.H. Lee, J-S. Lee, W-Z. Zhong, H. Horinouchi, W. Mao, S. Lu, Q. Wang, C-T. Yang, K. Korphaisarn, T. Xu, L. Bu, A. Scalori, P. Petric, K. Redhead, B. Solomon
Journal: Annals of Oncology (2023)
542P First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Authors: Y-L. Wu, Z. Wang, X. Dong, J. Li, L. Wu, L. Han, X. Li, A. Zang, W. Li, G. Wen, W. Lin, J. Feng, L. Wang, J. Li, Q. Wang, J. Zhu
Journal: Annals of Oncology (2023)
489TiP BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Authors: J. He, P. Zhang, H. Liu, W. Liang, W. Yu, J. Shi, B. Wei, W. Zheng, Z. Shen, N. Wu
Journal: Annals of Oncology (2023)
535P Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Authors: H.G. Luna, M.S. Imasa, N.S. Juat, K.V. Hernandez, T.M. Sayo, G.R. Cristal Luna, S.M. Asur-Galang, M. Bellengan, K.J.L. Duga, B.B. Buenaobra, M. De los Santos, D. Medina, V.M. Literal, N.A. Bascos
Journal: Annals of Oncology (2023)
533P Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Authors: T. Yamaguchi, R. Matsuzawa, M. Morise, K. Ito, O. Hataji, K. Takahashi, J. Koyama, Y. Kuwatsuka, Y. Goto, K. Imaizumi, H. Itani, Y. Zenke, M. Oki, M. Ishii
Journal: Annals of Oncology (2023)
447P Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Authors: N.S. Menon, V. Noronha, O. Row Chowdhury, A.R. Pawar, V.M. Patil, A.C. Singh, S. More, S. Goud, A. Yadav, M.J. Shah, K.N. Jobanputra, D.K. Shah, K. Prabhash
Journal: Annals of Oncology (2023)
455P Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Authors: F. Scotté, L. Zelek, C. Giuliano, S. Olivari Tilola, W.L. Bailey, C.H. Ruhlmann, H. Iihara, M.S. Aapro
Journal: Annals of Oncology (2023)
450P Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Authors: M.O. Okada, A. Ohba, S. Mitsunaga, T. Shibuki, T. Satake, K. Watanabe, M. Sasaki, H. Imaoka, Y. Maruki, Y. Nagashio, S. Kondo, H. Susumu, C. Morizane, H. Ueno, M. Ikeda, T. Okusaka
Journal: Annals of Oncology (2023)
554P Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Authors: K. Miyazaki, K. Ito, A. Hayashi, A. Shiba, Y. Higashi, M. Aga, Y. Hamakawa, Y. Taniguchi, Y. Misumi, Y. Agemi, Y. Nakamura, T. Shimokawa, H. Okamoto
Journal: Annals of Oncology (2023)
528P Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Authors: K.M. Cheung, C.H.L. Wong, J.C.H. Chow, K.K.H. Bao, K.S.J. Fong, V.H.F. Lee, M.Y. Lim, T.Y. Kam, S.F. Nyaw, C.K. Kwan, F. Mok, A.W.M. Lee, J.C.S. Ho
Journal: Annals of Oncology (2023)
549P Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Authors: S. Fujimoto, T. Tanaka, N. Katsurada, D. Hazama, T. Nagano, M. Yamamoto, M. Tachihara
Journal: Annals of Oncology (2023)
504P Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Authors: P.K. Marimuthu, A. Singh, A. Joel, D.B. Thumaty, J.T. Georgy, A.O. John, Z. Thomas, J.P. Wisely, S. Devabhaktuni, P. Jambunathan, H. Kovilapu, R. Isiah, S.P. Pavamani, B.K. Sasidharan, A. Irodi, T. Alex, R.T. Chacko
Journal: Annals of Oncology (2023)
543P A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Authors: Y. Ishida, S. Ikeda, T. Harada, J. Sakakibara-Konishi, K. Yokoo, H. Kikuchi, T. Iwasawa, T. Misumi, S. Konno, T. Ogura
Journal: Annals of Oncology (2023)
248P Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Authors: E. Al Masoud, S. Alzghoul, L. Lataifeh, B. Abu Mousa, A.H. Al Sharie
Journal: Annals of Oncology (2023)
280P Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Authors: K.M. Chiang, Y-H. Chou, S-W. Huang, L-H. Yuan, Y-W. Huang, Y-J. Chen, H-J. Yu, J-P. Chen
Journal: Annals of Oncology (2023)
253TiP WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Authors: Y. Bao, X. Liao, P. Zhang, H. Zeng, J. Liu, Q. Wei
Journal: Annals of Oncology (2023)
595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Authors: D-W. Kim, K. Goto, A. Schram, A. Hollebecque, S.Y. Rha, K. Nishino, M. Duruisseaux, K. Umemoto, J.O. Park, N. Leighl, T. Macarulla Mercade, S.V. Liu, M.N. Al-Hallak, J. Cleary, C. Neuzillet, Y. Goto, A.K. Joe, S. Adeyemi, S. Jauhari, A. Drilon
Journal: Annals of Oncology (2023)
399P Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Authors: Y. Arihara, R. Shibuya, M. Ono, N. Suzuki, G. Ohmori, Y. Ikeda, M. Yamada, T. Abe, K. Takada, M. Maeda
Journal: Annals of Oncology (2023)
346P An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Authors: I-C. Song, T.T.D. Pham, S.Y. Choi, B.Y. Heo, M. Lee, J.S. Koh, D-Y. Jo, J. Kwon
Journal: Annals of Oncology (2023)
464P The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Authors: M. Xiao, X. Chen, X. Qian, L. Ji, M. Xiu, Z. Li, H. Cao, S. Chen, Q. Li, Q. Li, X. Wang, J. Wang, Y. Li, B. Xu, P. Zhang
Journal: Annals of Oncology (2023)
181P TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Authors: Z. Huang, J. Zhou, M. Yang, W. Zhang, Y. Sun, H. Lu, H. Wang, X. Bi, Y. Zhang, J. Zhao, Y. Yang, B. Zhang, F. Ye, H. Zhao
Journal: Annals of Oncology (2023)
194P Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Authors: Q. Xu, J. Ying, L. Zhang, J. Li, P. Zeng, X. Yuan, Y. Huang
Journal: Annals of Oncology (2023)
187P Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Authors: P. Tao, Y. Wei, G. Zhu, Z. Zeng, Z. Lv, J. Ma, X. Ye, H. Su, K. Xiao, J. Liao, M. Su, S. Yu, L. Long, J. Wang, N. Peng, K. Zhao, C. Han, X. Liao, W. Qin, C. Yang
Journal: Annals of Oncology (2023)
596P Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Authors: S. Lu, X. Hu, S-W. Kim, K. Goto, N. Yang, R.A. Soo, J. Fang, W. Yao, K.H. Lee, D.W-T. Lim, T. Kato, M. Tamiya, J. Wu, Y. Zhang, J. Zhou, F. Ades, J. Hua, P.T. Wang, B.C. Cho
Journal: Annals of Oncology (2023)
197P Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Authors: Y. Zhang, J. Zhang, X. Xie, W. Pan, G. Wang, Q. Dong, N. Zhang, J. Dong, G. Segall, L. Zhou, C. Zhou, M. Khanal, Y. Yang, L. Zeng
Journal: Annals of Oncology (2023)
Hypertension &amp; dementia: Pathophysiology &amp; potential utility of antihypertensives in reducing disease burden
Authors: Mara Lyon, Josie L. Fullerton, Simon Kennedy, Lorraine M. Work
Journal: Pharmacology & Therapeutics (2023)

Dementia is a common cause of disability and dependency among the elderly due to its progressive neurodegenerative nature. As there is currently no curative therapy, it is of major importance to identify new ways to reduce its prevalence. Hypertension is recognised as a modifiable risk factor for dementia, particularly for the two most common subtypes; vascular dementia (VaD) and Alzheimer's disease (AD). From the current literature, identified through a comprehensive literature search of PubMed and Cochrane Library, this review aims to establish the stage in adulthood when hypertension becomes a risk for cognitive decline and dementia, and whether antihypertensive treatment is effective as a preventative therapy. Observational studies generally found hypertension in mid-life (age 45-64) to be correlated with an increased risk of cognitive decline and dementia incidence, including both VaD and AD. Hypertension manifesting in late life (age ≥ 65) was demonstrated to be less of a risk, to the extent that incidences of high blood pressure (BP) in the very elderly (age ≥ 75) may even be related to reduced incidence of dementias. Despite the evidence linking hypertension to dementia, there were conflicting findings as to whether the use of antihypertensives was beneficial for its prevention and this conflicting evidence and inconsistent results could be due to the methodological differences between the reviewed observational and randomised controlled trials. Furthermore, dihydropyridine calcium channel blockers and potassium-sparing diuretics were proposed to have neuroprotective properties in addition to BP lowering. Overall, if antihypertensives are confirmed to be beneficial by larger-scale homogenous trials with longer follow-up durations, treatment of hypertension, particularly in mid-life, could be an effective strategy to considerably lower the prevalence of dementia. Furthermore, greater clarification of the neuroprotective properties that some antihypertensives possess will allow for better clinical practice guidance on the choice of antihypertensive class for both BP lowering and dementia prevention.
88TiP A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Authors: N. Pavlakis, M. Millward, G. Richardson, V. Andelkovic, G. Kichenadasse, D.M. Thomas, A. Mas Fernandez, D. Thakkar, T. Arbabzade, C.H. Goey, Q. Seet, W. Toy, K. Paszkiewicz, P.J. Ingram, J.D. Boyd-Kirkup, K.Y. Kwek
Journal: Annals of Oncology (2023)
442P Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Authors: Y. Nisha, B. Dubashi, Z. Bobby, J.P. Sahoo, S. Kayal, R. Ananthakrishnan, V.B. Reddy, C. L, P. Ganesan
Journal: Annals of Oncology (2023)
377P Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Authors: P. Verma, A. R, P. Ku, R.M. P, N.K. Haridas, W.M. Jose, K. Thankappan, S. Iyer, K. Pavithran, D. Dutta
Journal: Annals of Oncology (2023)
586P Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Authors: C. Zhou, B. Li, J. Fang, J. Zhou, Y. Hu, C. Zhu, V. Bunn, M. Lin, J-L. Hong, J. Huang, J. Wang, R.J. Fram, S. Vincent, Y. Li
Journal: Annals of Oncology (2023)
408P Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Authors: C.J. Yen, M. Qing, X. Lyu, M. Gormley, J. Curtin, M. Xia, F. Yang, L. Zhou
Journal: Annals of Oncology (2023)
430MO Impact of Nada yoga music therapy on anxiety and quality of life in ovarian cancer patients: A randomized controlled trial
Authors: S. Malik, A. Sehrawat, R. Kumari, S.L. Barnwal, S. Kalra, R. Singh, P. Bhardwaj, T. Dogra, S. Gupta, S. Saini, N. Sinha, J. Chaturvedi
Journal: Annals of Oncology (2023)
381P P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Authors: S.L. Anwar, G.D. Pradana, H.Y. Boediman, R. Cahyono, W. Sugandhi, E.K. Dwianingsih
Journal: Annals of Oncology (2023)
568P First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Authors: D. Planchard, A. Poltoratskiy, S-W. Kim, T.M. Kim, N. Yanagitani, H. Kagamu, P-H. Feng, B. Hughes, T-Y. Yang, J.C-H. Yang, C.K. Lee, N. Karaseva, P. Mitchell, Y. Tambo, E. Armenteros Monterroso, A. Todd, A. Sahasrabudhe, P.A. Jänne, K. Kobayashi
Journal: Annals of Oncology (2023)
378P A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Authors: Z. Liu, D.Z. Li, J. li, H.L. Dong, W. Zhang, J. Wang, D.N. Huang, H.M. Wei, Y. Xu, T. Lu, C. Cui, H.W. Liu, Y.G. Li, C.J. Xu
Journal: Annals of Oncology (2023)
566P Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Authors: C.K. Liam, T.M. Kim, J-J. Yang, C. Huang, P-J. Voon, L.M. Tho, Q. Zhou, J. Wang, H. Hayashi, D.S.W. Tan, P. Danchaivijitr, V.N. Nguyen, K.H. Wong, J.C-H. Yang, X. Le, B. Ellers-Lenz, N. Karachaliou, V. Ghori, K. Berghoff, Y-L. Wu
Journal: Annals of Oncology (2023)
370P Low-dose nivolumab with induction chemotherapy for inoperable HNSCC in 111 patients: Response rates, survival, and implications for LMICs
Authors: J.T. Georgy, Z. Thomas, R.V. Georgy, S. Regi, A. Joel, D.B. Thumaty, A.O. John, S. Devabhaktuni, J.P. Wisely, P.K. Marimuthu, P. Jambunathan, H. Kovilapu, J.P. Rao, A. Tirkey, B.K. Sasidharan, R. Isiah, M. Thomas, R.T. Chacko, A. Singh
Journal: Annals of Oncology (2023)
355O Artificial intelligence-powered spatial analysis of tumor microenvironment (TME) in nasopharyngeal carcinoma (NPC) patients treated with immune checkpoint inhibitors (ICI)
Authors: B. Keam, D.W-T. Lim, C-Y. Ock, T. Lee, C. Oum, H-F. Kao, J. Yeong, B.C. Goh, S.H. Tan, E.P. Hui, H.A. Jung, K-U. Park, S-H. Cho, K-W. Lee, A.T.C. Chan, B. Ma
Journal: Annals of Oncology (2023)